Yu Shuting, Zhu Yingying, Shi Xiaohua, Hu Ke, Bai Chunmei, Diao Wenwen, Zhu Xiaoli, Gao Zhiqiang, Chen Xingming
Department of Otolaryngology-Head and Neck Surgery, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Department of Pathology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Cancer Manag Res. 2020 May 29;12:4063-4071. doi: 10.2147/CMAR.S250621. eCollection 2020.
To date, no guidelines have been proposed for the ideal treatment of postoperative larynx squamous cell carcinoma (LSCC) patients with lymphovascular invasion due to a lack of similar studies. The present study was conducted to compare the survival and toxicity in LSCC patients with lymphovascular invasion receiving either postoperative radiotherapy (PORT) or postoperative chemoradiotherapy (POCRT). The results can be applied for more appropriate treatment of these patients.
Three hundred eighty-eight eligible LSCC patients with lymphovascular invasion were enrolled in this retrospective study. Survival and treatment-related toxicities were compared in the POCRT and PORT group using propensity score matching (PSM) methodology (1:1).
Five-year overall survival (OS), disease-specific survival (DSS), and recurrence-free survival (RFS) of all patients were 48.7%, 58.2%, and 56.0%, respectively. Significantly, higher RFS rates (P=0.040) were found in the POCRT group than the PORT group in the PSM cohort. In the multivariate analysis, higher OS, DSS, and RFS rates were observed in the POCRT group than the PORT group (P=0.049, 0.024, and 0.011 respectively). Patients in the POCRT group presented more acute toxicities than those in the PORT group such as hematological toxicities (25.0% vs 0.9%, P<0.001) and mucositis (35.0% vs 19.1%, P=0.002).
In the context of no ideal treatment for LSCC patients with lymphovascular invasion, the present study proposes POCRT as a preferable modality compared with PORT, as POCRT was associated with higher RFS rates. Higher RFS, DFS, and OS rates were also observed in the POCRT group in the multivariate analysis.
迄今为止,由于缺乏类似研究,尚未有针对术后伴有淋巴管侵犯的喉鳞状细胞癌(LSCC)患者的理想治疗指南。本研究旨在比较接受术后放疗(PORT)或术后放化疗(POCRT)的伴有淋巴管侵犯的LSCC患者的生存率和毒性反应。研究结果可用于更合理地治疗这些患者。
388例符合条件的伴有淋巴管侵犯的LSCC患者纳入本回顾性研究。采用倾向评分匹配(PSM)方法(1:1)比较POCRT组和PORT组的生存率及治疗相关毒性反应。
所有患者的5年总生存率(OS)、疾病特异性生存率(DSS)和无复发生存率(RFS)分别为48.7%、58.2%和56.0%。值得注意的是,PSM队列中POCRT组的RFS率显著高于PORT组(P = 0.040)。多因素分析显示,POCRT组的OS、DSS和RFS率均高于PORT组(分别为P = 0.049、0.024和0.011)。POCRT组患者出现的急性毒性反应比PORT组更多,如血液学毒性(25.0%对0.9%,P < 0.001)和黏膜炎(35.0%对19.1%,P = 0.002)。
在没有针对伴有淋巴管侵犯的LSCC患者的理想治疗方案的情况下,本研究提出与PORT相比,POCRT是一种更优的治疗方式,因为POCRT与更高的RFS率相关。多因素分析中POCRT组的RFS、DFS和OS率也更高。